(Part 3) Adjunctive use of sealants, glues…

 (Continued from here)

The dynamics behind these products’ success: 

  • Significant cost-effectiveness arguments can be made for products that avoid blood transfusions or reduce the quantities of blood transfusion products required. Approximately 8 million patients worldwide would benefit directly from increased usage of hemostats, sealants and glue products to reduce bleeding during cardiovascular, orthopaedic, urologic, and other general surgical procedures. Units of blood cost approximately $180 each; however, the benefit of reducing transfusion requirement goes beyond this simple saving. Often, the real benefit is that appropriate hemostasis reduces the risk of mortality. For example, reducing blood loss during cardiovascular procedures in particular not only prevents the use of large volumes of donated blood (e.g., 5–10 units for dissection of aortic aneurysms) but significantly reduces mortality rates (which can be as high as 30% for aortic aneurysm procedures).
  • Adhesion-prevention products have been shown to significantly reduce post-surgical adhesions associated with gynaecological, spinal, cardiovascular and orthopedic procedures. Post-operative adhesions can severely complicate subsequent interventions by making re-entry hazardous, and impeding orientation and visibility, which can lead to damaging the surrounding tissues or vessels. There may also be increased blood loss, and significantly longer operating time required to cut through the adhesions.


These dynamics have collectively contributed to the worldwide growth in the market.  Below please find the aggregate worldwide market forecast for these products.


Worldwide Growth in the Markets for
Sealants, Glues, Wound Closure and Anti-Adhesion,


















 Source: Report #S175, published December 2008, MedMarket Diligence, LLC

Adjunctive use of sealants, glues, hemostasis and other wound closure and anti-adhesion (part 1)

There are many reasons underlying the explosive growth of the worldwide markets for surgical sealants, hemostasis, wound closure and anti-adhesion.

The market potential for products in the surgical securement field is driven by a combination of new technologies coming to market and expanding caseload for which these technologies are applicable. The potential for these products continues to grow as surgical practices improve and the benefits of new products address the requirement for fast and effective closure.

We forecast that approximately 70 million procedures around the world might benefit from products in this category in the future, and due to demographic trends and evolving surgical capabilities, this number is forecast to increase at an annualized rate of 3%–5%.  

In the coming decade we will see strong penetration of new therapies into new procedure areas and some new introductory techniques for treatment of orthopedic, cardiovascular and neurological procedures.

Below represent some of the clinical and market dynamics for these products’ success:

  • The use of products such as tapes and sutures for wound closure and securement leads to faster wound healing with less risk of contamination by debris and infectious agents, and with improved cosmetic outcomes. Failure to use these products can lead to significant complications, infections, significant delays to healing, and potentially loss of life through infection of the tissue leading to septicemia.
  • Hemostats, sealants and glues have been shown to aid recovery and rehabilitation after invasive surgical procedures, to reduce morbidity associated with infection rates and post-surgical adhesions, and to reduce morbidity associated with specific procedures. For example, these products may be used to reduce the risk of deep vein thromboses resulting from tourniquet application to reduce bleeding during total knee replacements.
  • Hemostats and sealants have been demonstrated to have substantial cost-effective benefits during many surgical operations and the cost of these products are increasingly seen as minor in comparison with the time saved during the surgical procedure alone, even without taking into account rehabilitation. These products have been shown to be highly cost-effective for topical wound closure and there are also many potential internal applications for these products.

To be continued..

See Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009, published December 2008.


Expanded list of companies in med/surg sealants, glues, hemostasis, anti-adhesion, wound closure

The list of companies profiled in the forthcoming MedMarket Diligence report #S175 on Surgical Sealants, Glues, Wound Closure and Anti-Adhesion has been expanded based on the additional company data gathered from the worldwide analysis.  The list now stands at 136 companies.  See below:

4.1 3DM, Inc. (3D-Matrix, Ltd.)
4.2 3M
4.3 Abbott Vascular
4.4 AccessClosure, Inc.
4.5 Adhezion Biomedical, LLC
4.6 Advanced Medical Solutions
4.7 Allerderm
4.8 Angiotech Pharmaceuticals, Inc.
4.9 Anika Therapeutics, Inc.
4.10 ARC Pharmaceuticals Inc.
4.11 Arch Therapeutics (formerly Clear Nano Solutions)
4.12 ArthroCare Corporation
4.13 ASO LLC
4.14 Aspen Surgical Products
4.15 Atrax Medical Group
4.16 Avery Dennison
4.17 B. Braun Melsungen AG
4.18 Bard Medical Division, CR Bard
4.19 Bastos Viegas, s.a.
4.20 Baxter International Inc.
4.21 Bayer HealthCare
4.22 BD (Becton Dickinson and Company)
4.23 Berlin Heart GmbH
4.24 Bernsco Surgical Supply
4.25 Biocoral Inc
4.26 BioCore Medical Technologies, Inc.
4.27 Biogentis, Inc.
4.28 Biomet, Inc.
4.29 BIOSTER a.s.
4.30 BSN Medical
4.31 Cardiovascular Sciences, Inc.
4.32 Cardiva Medical, Inc.
4.33 Carl Auffarth GmbH & Co. KG
4.34 Ceremed, Inc.
4.35 Chemence Ltd.
4.36 Chemopharma, s.a.
4.37 Cohera Medical, Inc.
4.38 Collagen Matrix, Inc.
4.39 Coloplast A/S
4.40 ConvaTec
4.41 Covidien
4.42 CryoLife, Inc.
4.43 CSIRO PhotoMedical Technologies
4.44 CSL Behring
4.45 CSMG Technologies, Inc.
4.46 CuraMedical BV
4.47 Cypress Medical Products
4.48 DePuy, Inc.
4.49 Derma Sciences
4.50 Distrex Ibérica S.A.
4.51 Entegrion
4.52 Ethicon, Inc., Johnson & Johnson
4.53 FibroGen, Inc.
4.54 Fidia Advanced Biopolymers SpA
4.55 Flamel Technologies SA
4.56 Focal, Inc.
4.57 Forticell Bioscience
4.58 FzioMed, Inc.
4.59 Gelita Medical BV
4.60 GEM s.r.l.
4.61 Genzyme Biosurgery
4.62 GluStitch, Inc.
4.63 Graceduty Company Limited
4.64 GramsMed, LLC
4.65 Haemacure Corporation
4.66 HAPTO Biotech Israel Ltd.
4.67 Hartmann Group
4.68 Harvest Technologies Corporation
4.69 HemCon Medical Technologies, Inc.
4.70 Hemostasis LLC
4.71 HyperBranch Medical Technology, Inc.
4.72 Incisive Surgical, Inc.
4.73 Innovasa Corporation
4.74 Integra Lifesciences Corporation
4.75 I-Therapeutix, Inc.
4.76 Kaketsuken (Chemo-Sero-Therapeutic Research Institute)
4.77 Kensey Nash Corporation
4.78 Kimberly-Clark Health Care
4.79 Kinetic Concepts, Inc.
4.80 King Pharmaceuticals, Inc.
4.81 Kookbo Chemicals Co., Ltd. (KB Chem.)
4.82 Laboratoires Urgo (Urgo Medical)
4.83 Lewis Medical Supplies
4.84 LifeBond, Ltd.
4.85 Lifecore Biomedical Inc.
4.86 Lohmann & Rauscher
4.87 Marine Polymer Technologies
4.88 Medafor, Inc.
4.89 Medi Surgichem Pvt. Ltd.
4.90 MedTrade Products
4.91 Meyer-Haake GmbH Medical Innovations
4.92 Mölnlycke Health Care AB
4.93 Morris Innovative
4.94 Motex Healthcare Corp.
4.95 Myco Medical
4.96 NeatStitch Ltd.
4.97 Neose Technologies Inc.
4.98 Nycomed
4.99 Nycomed Pharma AS
4.100 Omrix Biopharmaceuticals Inc. (J&J)
4.101 Pac-Kit Safety Equipment
4.102 Pfizer Inc.
4.103 Pharming Group NV
4.104 Plasma Technologies, Inc.
4.105 PlasmaSeal LLC
4.106 Pluromed, Inc.
4.107 Polyganics, BV
4.108 Polyheal Ltd.
4.109 ProFibrix BV
4.110 Progressive Surgical, Ltd.
4.111 Protein Polymer Technologies, Inc.
4.112 Radi Medical Systems AB
4.113 Resorba Wundversorgung GmbH & Co. KG
4.114 Scapa Group plc
4.115 Scion Cardio-Vascular, Inc.
4.116 Sea Run Holdings
4.117 Seton
4.118 Smith & Nephew Plc
4.119 Starch Medical, Inc.
4.120 Stereoplast Ltd.
4.121 Sutura Inc.
4.122 Synovis Life Technologies, Inc.
4.123 SyntheMed, Inc.
4.124 Teleflex Medical
4.125 ThermoGenesis Corp.
4.126 Therus Corporation
4.127 Thrombotargets Corp.
4.128 Tissuemed Ltd.
4.129 TraumaCure, Inc.
4.130 TyRx Pharma, Inc.
4.131 Vascular Solutions, Inc.
4.132 Vectura Group plc
4.133 Vivostat A/S
4.134 Zimmer
4.135 Z-Medica Corp.
4.136 ZymoGenetics, Inc.


Companies active in surgical glues, sealants, wound closure and anti-adhesion

The companies involved in the marketing and development of surgical sealants, glues, and other wound closure and anti-adhesion products are a robust group.  The number of competitors and the breadth and depth of their offerings are testimony to the size of the active market as well as its considerable potential.  Below is the list of companies preliminarily profiled in the pending, December 2008, report #S175, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-adhesion, 2009-2013."  The report is described here.
4.1      3DM, Inc. (3D-Matrix, Ltd.)
4.2      Abbott Vascular
4.3      AccessClosure, Inc.
4.4      Adhezion Biomedical, LLC 
4.5      Advanced Medical Solutions 
4.6      Angiotech Pharmaceuticals, Inc.
4.7      Anika Therapeutics, Inc.
4.8      ARC Pharmaceuticals Inc.
4.9      Arch Therapeutics (formerly Clear Nano Solutions)
4.10    ArthroCare Corporation
4.11    B. Braun Melsungen AG
4.12    Bard Medical Division, CR Bard
4.13    Baxter International Inc.
4.14    Bayer Schering Pharma
4.15    BD (Becton Dickinson and Company)
4.16    Biiosyntech Inc.
4.17    Biocoral Inc
4.18    Biogentis, Inc.
4.19    BIOSTER a.s.
4.20    Cardiovascular Sciences, Inc.
4.21    Cardiva Medical, Inc.
4.22    Ceremed, Inc.
4.23    Chemence Ltd.
4.24    Cohera Medical, Inc.
4.25    Collagen Matrix, Inc.
4.26    Covidien
4.27    CryoLife, Inc.
4.28    CSIRO PhotoMedical Technologies
4.29    CSL Behring
4.30    CSMG, Inc.
4.31    CuraMedical BV
4.32    DePuy, Inc.
4.33    Entegrion
4.34    Ethicon, Inc., Johnson & Johnson
4.35    FibroGen, Inc.
4.36    Fidia Advanced Biopolymers SpA
4.37    Flamel Technologies SA
4.38    Focal, Inc.
4.39    Forticell Bioscience
4.40    FzioMed, Inc.
4.41    GEM s.r.l.
4.42    Genzyme Biosurgery
4.43    GluStitch, Inc.
4.44    Haemacure Corporation
4.45    Harvest Technologies Corporation
4.46    HemCon, Inc.
4.47    Hemostasis LLC
4.48    Henkel Loctite Corp.
4.49    HyperBranch Medical Technology, Inc.
4.50    Innovasa Corporation
4.51    Integra Lifesciences Corporation
4.52    Interpore Cross International
4.53    Isto Technologies, Inc.
4.54    I-Therapeutix, Inc.
4.55    Kaketsuken (Chemo-Sero-Therapeutic Research Institute)
4.56    Kensey Nash Corporation
4.57    Kimberly-Clark Health Care
4.58    King Pharmaceuticals, Inc.
4.59    LifeBond, Ltd.
4.60    Lifecore Biomedical Inc.
4.61    Marine Polymer Technologies
4.62    Medafor, Inc.
4.63    MedTrade Products
4.64    Meyer-Haake GmbH Medical Innovations
4.65    Morris Innovative
4.66    Neose Technologies
4.67    Nycomed Pharma AS
4.68    Omrix Biopharmaceuticals Inc.
4.69    Organogenesis, Inc.
4.70    Pharming Group NV
4.71    Plasma Technologies, Inc.
4.72    PlasmaSeal LLC
4.73    Pluromed, Inc.
4.74    Polyganics, BV
4.75    ProFibrix BV
4.76    Protein Polymer Technologies, Inc.
4.77    Radi Medical Systems AB
4.78    Scion Cardio-Vascular, Inc.
4.79    Sea Run Holdings
4.80    Smith & Nephew Plc 
4.81    Sutura Inc.
4.82    Synovis Life Technologies, Inc.
4.83    Teleflex Medical
4.84    ThermoGenesis Corp.
4.85    Therus Corporation
4.86    Thrombotargets Corp.
4.87    Tissuemed Ltd.
4.88    TraumaCure, Inc.
4.89    TyRx Pharma, Inc. 
4.90    Vascular Solutions, Inc. 
4.91    Vectura Group plc 
4.92    Vivostat A/S
4.93    Z-Medica Corp.
See Report #S175 for more detail.